Last reviewed · How we verify

Restrictive Red blood cell transfusion

Assistance Publique - Hôpitaux de Paris · Phase 3 active Biologic

Restrictive Red blood cell transfusion is a Biologic drug developed by Assistance Publique - Hôpitaux de Paris. It is currently in Phase 3 development for Perioperative blood management in surgical patients, Critical illness requiring red blood cell transfusion support.

A clinical strategy that limits red blood cell transfusions to lower hemoglobin thresholds, reducing unnecessary transfusion exposure while maintaining adequate oxygen delivery.

A clinical strategy that limits red blood cell transfusions to lower hemoglobin thresholds, reducing unnecessary transfusion exposure while maintaining adequate oxygen delivery. Used for Perioperative blood management in surgical patients, Critical illness requiring red blood cell transfusion support.

At a glance

Generic nameRestrictive Red blood cell transfusion
SponsorAssistance Publique - Hôpitaux de Paris
ModalityBiologic
Therapeutic areaHematology / Critical Care / Perioperative Medicine
PhasePhase 3

Mechanism of action

Restrictive transfusion protocols use lower hemoglobin triggers (typically 7-8 g/dL) compared to liberal transfusion strategies (10 g/dL or higher) to minimize transfusion-related complications including infection, immunosuppression, and organ dysfunction. This approach relies on the body's compensatory mechanisms and is being evaluated in phase 3 trials to determine optimal safety and efficacy across different patient populations.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Restrictive Red blood cell transfusion

What is Restrictive Red blood cell transfusion?

Restrictive Red blood cell transfusion is a Biologic drug developed by Assistance Publique - Hôpitaux de Paris, indicated for Perioperative blood management in surgical patients, Critical illness requiring red blood cell transfusion support.

How does Restrictive Red blood cell transfusion work?

A clinical strategy that limits red blood cell transfusions to lower hemoglobin thresholds, reducing unnecessary transfusion exposure while maintaining adequate oxygen delivery.

What is Restrictive Red blood cell transfusion used for?

Restrictive Red blood cell transfusion is indicated for Perioperative blood management in surgical patients, Critical illness requiring red blood cell transfusion support.

Who makes Restrictive Red blood cell transfusion?

Restrictive Red blood cell transfusion is developed by Assistance Publique - Hôpitaux de Paris (see full Assistance Publique - Hôpitaux de Paris pipeline at /company/assistance-publique-h-pitaux-de-paris).

What development phase is Restrictive Red blood cell transfusion in?

Restrictive Red blood cell transfusion is in Phase 3.

What are the side effects of Restrictive Red blood cell transfusion?

Common side effects of Restrictive Red blood cell transfusion include Anemia-related complications, Tissue hypoxia, Organ dysfunction.

Related